Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib versus placebo for alveolar soft part sarcoma
ACTRN12612000020886Phase 2Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in alveolar soft part sarcoma (ASPS) comparing Cediranib with Placebo then cediranib crossover (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jun 2012; status: recruiting.
02
Drugs
cediranib
03
Conditions
alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on ACTRN12612000020886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000020886.